Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

ACC 2024 Congress

Catch up on all the top stories and latest evidence in cardiology research with our ACC 2024 Congress hub page.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2016

Open Access 01-12-2016 | Study protocol

The effectiveness of a nurse-led intervention with the distress thermometer for patients treated with curative intent for breast cancer: design of a randomized controlled trial

Authors: Floortje K. Ploos van Amstel, Judith B. Prins, Winette T. A. van der Graaf, Marlies E. W. J. Peters, Petronella B. Ottevanger

Published in: BMC Cancer | Issue 1/2016

Login to get access

Abstract

Background

Distress in patients with cancer influences their quality of life. Worldwide, screening on distress with the Distress Thermometer (DT) in patients with cancer is recommended. However, the effects of the use of the DT on the psychosocial wellbeing of the patient are unknown. A study to assess the psychosocial consequences of the systematic use of the DT and its discussion by a nurse as compared to the usual care provided to outpatients who are treated for primary breast cancer is needed.

Methods/design

The effectiveness of a nurse-led intervention with the DT will be tested in a non-blinded randomized controlled trial. Patients treated with curative intent for breast cancer will be recruited from the Radboud University Medical Center. The intervention consists of the DT together with discussion of the results with the patient by a trained oncology nurse added to the usual care. Patients will be randomly allocated (1:1) to either receive usual care or the usual care plus the intervention. Primary outcome measure is global quality of life measured with the EORTC QLQ-C30. The functional and symptom scales of the EORTC QLQ-C30 and BR23, Hospital Anxiety and Depression Scale, Impact of Event Scale, Illness Cognition Questionnaire and DT (baseline and final measurement only) will be used to measure secondary outcomes. Questionnaires are obtained in both arms at baseline, after completion of each type of cancer treatment modality and during follow up, with a three and six months’ interval during the first and second year respectively.

Discussion

This study will be the first randomized controlled longitudinal study about the effectiveness of the DT as nurse led-intervention. In case of proven effectiveness, future implementation and standardization of use of the DT as part of routine care will be recommended.

Trial registration

This study is registered at clinicaltrial.gov march 17, 2010 (NCT01091584).
Literature
1.
Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136(5):E359–386.CrossRefPubMed
2.
Brocken P, Prins JB, Dekhuijzen PN, van der Heijden HF. The faster the better? A systematic review on distress in the diagnostic phase of suspected cancer, and the influence of rapid diagnostic pathways. Psychooncology. 2012;21(1):1–10.CrossRefPubMed
3.
Fallowfield L, Jenkins V. Psychosocial/survivorship issues in breast cancer: are we doing better? J Natl Cancer Inst. 2015;107(1):335.CrossRefPubMed
4.
National Comprehensive Network Cancer Network. NCCN clinical practice guidelines in oncology: distress management V.2. 2013. Retrieved from www.​nccn.​org
5.
Vitek L, Rosenzweig MQ, Stollings S. Distress in patients with cancer: definition, assessment, and suggested interventions. Clin J Oncol Nurs. 2007;11(3):413–8.CrossRefPubMed
6.
Ryan H, Schofield P, Cockburn J, Butow P, Tattersall M, Turner J, Girgis A, Bandaranayake D, Bowman D. How to recognize and manage psychological distress in cancer patients. Eur J Cancer Care. 2005;14(1):7–15.CrossRef
7.
Falagas ME, Zarkadoulia EA, Ioannidou EN, Peppas G, Christodoulou C, Rafailidis PI. The effect of psychosocial factors on breast cancer outcome: a systematic review. Breast Cancer Res. 2007;9:4.CrossRef
8.
Groenvold M, Petersen MA, Idler E, Bjorner JB, Fayers PM, Mouridsen HT. Psychological distress and fatigue predicted recurrence and survival in primary breast cancer patients. Breast Cancer Res Tr. 2007;105(2):209–19.CrossRef
9.
Ploos van Amstel FK, van den Berg SW, van Laarhoven HW, Gielissen MF, Prins JB, Ottevanger PB. Distress screening remains important during follow-up after primary breast cancer treatment. Support Care Cancer. 2013;21(8):2107–15.CrossRefPubMed
10.
Ploos van Amstel FK, van Ham MA, Peters EJ, Prins JB, Ottevanger PB. Self-reported distress in patients with ovarian cancer: is it related to disease status? Int J Gynecol Cancer. 2015;25(2):229–35.CrossRefPubMed
11.
Stanton AL. What happens now? Psychosocial care for cancer survivors after medical treatment completion. J Clin Oncol. 2012;30(11):1215–20.CrossRefPubMed
12.
Mehnert A, Koch U. Psychosocial care of cancer patients--international differences in definition, healthcare structures, and therapeutic approaches. Support Care Cancer. 2005;13(8):579–88.CrossRefPubMed
13.
Comprehensive Cancer Center Netherlands. Dutch guideline: detection of need for psychosocial care, version 1.0. 2010. Retrieved from www.​oncoline.​nl.
14.
Tuinman MA, Gazendam-Donofrio SM, Hoekstra-Weebers JE. Screening and referral for psychosocial distress in oncologic practice: use of the distress thermometer. Cancer. 2008;113(4):870–8.CrossRefPubMed
15.
Martinez P, Galdon MJ, Andreu Y, Ibanez E. The distress thermometer in Spanish cancer patients: convergent validity and diagnostic accuracy. Support Care Cancer. 2013;21(11):3095–102.CrossRefPubMed
16.
Thalen-Lindstrom A, Larsson G, Hellbom M, Glimelius B, Johansson B. Validation of the distress thermometer in a Swedish population of oncology patients; accuracy of changes during six months. Eur J Oncol Nurs. 2013;17(5):625–31.CrossRefPubMed
17.
Grassi L, Johansen C, Annunziata MA, Capovilla E, Costantini A, Gritti P, Torta R, Bellani M. Italian society of psycho-oncology distress thermometer study G. Screening for distress in cancer patients: a multicenter, nationwide study in Italy. Cancer. 2013;119(9):1714–21.CrossRefPubMed
18.
Snowden A, White CA, Christie Z, Murray E, McGowan C, Scott R. The clinical utility of the distress thermometer: a review. Br J Nurs. 2011;20(4):220–7.CrossRefPubMed
19.
Admiraal JM, Reyners AK, Hoekstra-Weebers JE. Do cancer and treatment type affect distress? Psychooncology. 2013;22(8):1766–73.CrossRefPubMed
20.
Chambers SK, Zajdlewicz L, Youlden DR, Holland JC, Dunn J. The validity of the distress thermometer in prostate cancer populations. Psychooncology. 2014;23(2):195–203.CrossRefPubMed
21.
Donovan KA, Grassi L, McGinty HL, Jacobsen PB. Validation of the distress thermometer worldwide: state of the science. Psychooncology. 2014;23(3):241–50.CrossRefPubMed
22.
Jacobsen PB, Donovan KA, Trask PC, Fleishman SB, Zabora J, Baker F, Holland JC. Screening for psychologic distress in ambulatory cancer patients. Cancer. 2005;103(7):1494–502.CrossRefPubMed
23.
Hegel MT, Moore CP, Collins ED, Kearing S, Gillock KL, Riggs RL, Clay KF, Ahles TA. Distress, psychiatric syndromes, and impairment of function in women with newly diagnosed breast cancer. Cancer. 2006;107(12):2924–31.CrossRefPubMed
24.
Hollingworth W, Metcalfe C, Mancero S, Harris S, Campbell R, Biddle L, McKell-Redwood D, Brennan J. Are needs assessments cost effective in reducing distress among patients with cancer? A randomized controlled trial using the distress thermometer and problem list. J Clin Oncol. 2013;31(29):3631–8.CrossRefPubMed
25.
Coyne JC. Second thoughts about implementing routine screening of cancer patients for distress. Psycho-Oncol. 2013;7(4):243–9.CrossRef
26.
27.
Meijer A, Roseman M, Delisle VC, Milette K, Levis B, Syamchandra A, Stefanek ME, Stewart DE, de Jonge P, Coyne JC, et al. Effects of screening for psychological distress on patient outcomes in cancer: a systematic review. J Psychosom Res. 2013;75(1):1–17.CrossRefPubMed
28.
Jacobsen PB, Wagner LI. A new quality standard: the integration of psychosocial care into routine cancer care. J Clin Oncol. 2012;30(11):1154–9.CrossRefPubMed
29.
Jacobsen PB, Ransom S. Implementation of NCCN distress management guidelines by member institutions. J Natl Compr Canc Netw. 2007;5(1):99–103.PubMed
30.
Chan AW, Tetzlaff JM, Gøtzsche PC, Altman DG, Mann H, Berlin J, Dickersin K, Hróbjartsson A, Schulz KF, Parulekar WR, et al. SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials. BMJ. 2013;346:e7586.CrossRefPubMedPubMedCentral
31.
Fontaine C, Meulemans A, Huizing M, Collen C, Kaufman L, De Mey J, Bourgain C, Verfaillie G, Lamote J, Sacre R, et al. Tolerance of adjuvant letrozole outside of clinical trials. Breast. 2008;17(4):376–81.CrossRefPubMed
32.
33.
Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, Filiberti A, Flechtner H, Fleishman SB, de Haes JC, et al. The European organization for research and treatment of cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993;85(5):365–76.CrossRefPubMed
34.
King MT. The interpretation of scores from the EORTC quality of life questionnaire QLQ-C30. Qual Life Res. 1996;5(6):555–67.CrossRefPubMed
35.
Osoba D, Aaronson N, Zee B, Sprangers M, te Velde A, The Study Group on Quality of Life of the EORTC and the Symptom Control and Quality of Life Committees of the NCI of Canada Clinical Trials Group. Modification of the EORTC QLQ-C30 (version 2.0) based on content validity and reliability testing in large samples of patients with cancer. Qual Life Res. 1997;6(2):103–8.CrossRefPubMed
36.
Sprangers MA, Groenvold M, Arraras JI, Franklin J, te Velde A, Muller M, Franzini L, Williams A, de Haes HC, Hopwood P, et al. The European Organization for Research and Treatment of Cancer breast cancer-specific quality-of-life questionnaire module: first results from a three-country field study. J Clin Oncol. 1996;14(10):2756–68.PubMed
37.
Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand. 1983;67(6):361–70.CrossRefPubMed
38.
Bjelland I, Dahl AA, Haug TT, Neckelmann D. The validity of the Hospital Anxiety and Depression Scale. An updated literature review. J Psychosom Res. 2002;52(2):69–77.CrossRefPubMed
39.
Spinhoven P, Ormel J, Sloekers PP, Kempen GI, Speckens AE, Van Hemert AM. A validation study of the Hospital Anxiety and Depression Scale (HADS) in different groups of Dutch subjects. Psychol Med. 1997;27(2):363–70.CrossRefPubMed
40.
Van der Ploeg E, Mooren TT, Kleber RJ, van der Velden PG, Brom D. Construct validation of the dutch version of the impact of event scale. Psychol Assess. 2004;16(1):16–26.CrossRefPubMed
41.
Evers AW, Kraaimaat FW, van Lankveld W, Jongen PJ, Jacobs JW, Bijlsma JW. Beyond unfavorable thinking: the illness cognition questionnaire for chronic diseases. J Consult Clin Psychol. 2001;69(6):1026–36.CrossRefPubMed
42.
Hoeymans N, van Lindert H, Westert GP. The health status of the Dutch population as assessed by the EQ-6D. Qual Life Res. 2005;14(3):655–63.CrossRefPubMed
43.
Metadata
Title
The effectiveness of a nurse-led intervention with the distress thermometer for patients treated with curative intent for breast cancer: design of a randomized controlled trial
Authors
Floortje K. Ploos van Amstel
Judith B. Prins
Winette T. A. van der Graaf
Marlies E. W. J. Peters
Petronella B. Ottevanger
Publication date
01-12-2016
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2016
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-016-2565-x

Other articles of this Issue 1/2016

BMC Cancer 1/2016 Go to the issue

Research article

The anti-oxidative transcription factor Nuclear factor E2 related factor-2 (Nrf2) counteracts TGF-β1 mediated growth inhibition of pancreatic ductal epithelial cells -Nrf2 as determinant of pro-tumorigenic functions of TGF-β1

Research article

Optimizing the process of fertility preservation in pediatric female cancer patients – a multidisciplinary program

Research article

Incidence and Survival of urothelial carcinoma of the urinary bladder in Norway 1981-2014

Research article

Circulating proteins in response to combined-modality therapy in rectal cancer identified by antibody array screening

Research article

Quality of life after cancer—How the extent of impairment is influenced by patient characteristics

Research article

In vitro and in vivo activity of melflufen (J1) in lymphoma
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits